Expiration date: 03/2026
Composition
One suppository contains:
Active ingredient: diindolylmethane 100 mg,
auxiliary substances: solid fat (Vitepsol H-15) (1.9795 g), crospovidone (collidone CL) (0.0200 g), carmine red dye, E 120 (0.0005 g).
Dosage form
of vaginal suppositories
Description
Suppositories are light pink to yellowish pink in color, torpedo-shaped.
Pharmacodynamics
The drug Cervicon-DIM contains diindolylmethane as an active ingredient, which is a means of stimulating apoptosis of infected human papillomavirus (HPV) and transformed cells, as well as a stimulator of the expression of k-interferon receptors. Thus, the therapeutic effect of diindolylmethane is based on its ability to accelerate the elimination of human papillomavirus infected and transformed cells and enhance the nonspecific immune response to infection.
In addition, diindolylmethane normalizes estradiol metabolism in HPV-infected cells, preventing the formation of a carcinogenic metabolite of estrogen (16-hydroxyestrone), which stimulates the expression of HPV oncogenes. By suppressing the expression of the human papillomavirus oncogene E7, diindolylmethane blocks the hormone-dependent pathological proliferation of HPV-infected cells.
Diindolylmethane belongs to practically non-toxic drugs (LD50 more than 5 g /kg).
Pharmacokinetics
With intravaginal use, diindolylmethane has a high local bioavailability and at the same time practically does not enter the systemic circulation.
Indications for use
Treatment of cervical dysplasia (cervical intraepithelial neoplasia) (regardless of the results of detection of papillomavirus infection by PCR).
Contraindications
Individual intolerance to any of the components of the drug.
The period of pregnancy and breastfeeding.
Children under the age of 18.
Use during pregnancy and lactation
It is contraindicated to use the drug during pregnancy and during breastfeeding.
Side effects
The drug is usually well tolerated by patients. In some cases, the following usually reversible adverse events may occur.
The adverse events presented below are listed depending on the anatomical and physiological classification and frequency of occurrence.
The frequency of side effects is classified by WHO and has gradations: very often (1/10), often (1/100 and <,1/10), infrequently (1/1000 and <,1/100), rarely (1/10000 and <,1/1000), very rarely (<,1 /10000), not established.
Undesirable phenomena
Often ( 1/100 and <,1/10)
Infrequently (1/1000 and <,1/100)
Disorders of the immune system
hives, itching
Disorders of the heart
shortening of the atrioventricular conduction
Vascular disorders
increased blood pressure
Disorders of the gastrointestinal tract
diarrhea
Disorders of the skin and subcutaneous tissues
petechial rash on the skin, slowing down the growth of hair on the head, body
Disorders of the genitals and breast
discomfort, burning, itching in the vagina, whiteness and flocculent discharge from the genital tract
vaginal dryness during sexual contact, delayed menstruation
Laboratory and instrumental data
increased activity of aspartate aminotransferase and alanine aminotransferase in blood plasma, thrombocytopenia and increased erythrocyte sedimentation rate, bacteriuria, leukocyturia, proteinuria, ketonuria
decreased creatinine concentration in blood plasma, leukocytosis in a cervical smear, vaginal dysbiosis, signs of myocardial hypoxia on an electrocardiogram
If any of the adverse reactions listed in the instructions manifest or worsen, or if you notice any other adverse reactions not listed in the instructions, inform your doctor.
Interaction
It has not been studied.
Due to the lack of systemic pharmacokinetics, no interaction with drugs of systemic use is expected.
The drug should not be used simultaneously with local drugs for intravaginal use belonging to the group of antiseptic oxidants (potassium permanganate, iodine, hydrogen peroxide).
Method of administration and dosage
Intravaginally, 100 mg 2 times a day. The duration of the course of treatment is 3-6 months. The duration of treatment is determined by the dynamics of clinical laboratory parameters.
Recommendations on the method of administration of the drug:
The drug is injected into the vagina 2 times a day (morning and evening) for 1 suppository.
Wash your hands thoroughly immediately before administration. The suppository is inserted deep into the vagina in a lying position. After administration, it is recommended to use a sanitary pad.
Overdose
The symptoms of overdose are unknown.
Special instructions
In the treatment of vaginal infections, the drug should not be used during menstruation, it is advisable to start treatment after menstruation.
During the treatment period, it is recommended to refrain from sexual intercourse.
During treatment, it is recommended to use contraceptives.
Influence on the ability to drive vehicles and manage mechanisms
The drug Cervicon-DIM does not affect the ability to control vehicles and mechanisms.
Release form
Vaginal suppositories, 100 mg.
Packaging
5 or 10 suppositories in a contour cell package made of polyvinyl chloride film.
2, 3, 5, 7, 9 contour cell packages No. 5 together with the instructions for use are placed in a pack of cardboard.
By 2, 3, 4, 5, 6, 7, 8, 9, 10 contour cell packages No. 10, together with the instructions for use, are placed in a pack of cardboard.
Conditions of release from pharmacies
By prescription
Storage conditions
In a place protected from light, at a temperature from 2 C to 8 C.
Keep out of reach of children.
Expiration date
2 years. After the expiration date, do not use the drug.
